Infectious Disease Research Institute Receives BARDA Funding for Development of RNA Vaccine Against Intranasal Influenza | National company
SEATTLE – (BUSINESS WIRE) – December 14, 2021–
the Infectious Disease Research Institute (IDRI), a Seattle-based not-for-profit biotech research institute, today announced a contract with the Biomedical Advanced Research and Development Authority (BARDA) DRIVe (Division of Research, Innovation, and Ventures) ” Beyond the needle ”To develop an intranasally administered RNA vaccine for pandemic influenza.
Beyond the Needle funds the development of new technologies to facilitate the delivery of vaccines and therapies, ultimately creating globally accessible vaccines. The development of an influenza vaccine administered intranasally using the IDRI RNA vaccine platform could improve the protection of the RNA vaccine against respiratory viruses, removing the need for the deep cold chain that makes RNA vaccines inaccessible to low- and middle-income countries (LMICs) and alleviate fears among hesitant individuals. BARDA has contracted with IDRI for the development of an intranasal RNA vaccine platform with long-term storage stability using H5N1 influenza as an initial proof of concept target.
“IDRI’s RNA platform has improved stability over current RNA vaccines, which directly address the challenges of cold chain distribution, allowing increased access to vaccines in locations where freezers and even refrigeration is not always readily available, ”said Alana Gerhardt, PhD, Senior Manager of Process Development, who will support the optimization of the vaccine platform for thermostability and intranasal delivery.
“Intranasal administration of RNA vaccines may offer improved protection against respiratory pathogens – along with easier administration and potentially higher absorption rates – compared to injected vaccines,” said Emily Voigt, PhD , Senior Director of the RNA Program. “Powerful vaccines combined with ease of administration, even by untrained medical personnel, and increased stability means we can reach more people faster and provide the protection needed against respiratory viruses, no matter where they are.” where you live.”
IDRI will provide the results of its BARDA-funded research as project milestones are achieved throughout the 2-year contract. IDRI plans to build on this work to make potent RNA vaccines cheaper and easier to manufacture, store, ship and administer around the world.
This project was funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50121C00087.
IDRI is a Seattle, Washington, nonprofit biotechnology organization that combines high-quality scientific research with product development and manufacturing capabilities to help fight some of the most common diseases. deadliest in the world, including COVID-19. For nearly three decades, much of IDRI’s work has focused on creating immune-boosting technologies that enhance the body’s natural response to disease. IDRI’s mission is to make these technologies widely available at low cost and to build a world in which everyone has access to the tools that harness their immune system and allow them to live long, healthy lives free from disease.
View source version on businesswire.com:https://www.businesswire.com/news/home/20211214005444/en/
CONTACT: Casey Benadof
KEYWORD: UNITED STATES NORTH AMERICA WASHINGTON
INDUSTRY KEYWORD: INFECTIOUS DISEASES BIOTECHNOLOGY HEALTH
Copyright Business Wire 2021.
PUB: 12/14/2021 08:00 / DISC: 12/14/2021 08:00
Copyright Business Wire 2021.